Overview

Next-generation sequencing has reshaped how clinicians approach advanced non-small cell lung cancer. Instead of testing one gene at a time, a focused panel surveys many genomic alterations from a single tissue or liquid sample. The 20-gene lung cancer assay offered here is built for exactly this purpose: to map the driver landscape of a tumor so that therapy can be matched to biology rather than to the organ of origin alone.

The Sequencing Workflow

At its core, this technology relies on sequencing by synthesis. Library fragments of tumor DNA are attached to a flow cell and amplified into clusters, after which fluorescent bases are read in parallel across millions of fragments. This massively parallel design lets a single run interrogate many loci at once. Bioinformatics pipelines then align the short reads to a reference genome and flag substitutions, insertions, deletions, and gene fusions that may be actionable.

Genes That Commonly Define the Targetable Landscape

Panels of this size typically cover the alterations that guideline bodies recognize in lung cancer. These include EGFR, ALK, ROS1, BRAF, MET exon 14 skipping, RET, ERBB2, KRAS, and the NTRK gene family. Detecting an EGFR mutation, an ALK or ROS1 rearrangement, or a BRAF change can point toward an approved targeted agent, while other variants open alternative routes. A broad panel reduces the chance that a treatable driver is missed because only one gene was examined.

Interpreting Results for Treatment Planning

A panel report does more than list variants. It usually provides allele frequency and copy-number context, which help distinguish clonal events from sub-clonal ones. That distinction is increasingly relevant when clinicians weigh first-line options against likely mechanisms of eventual resistance. Because the same tumor can carry more than one alteration, the report supports a prioritized, evidence-based therapy choice.

Choosing the Right Sample Type

Deciding between tumor tissue and a liquid biopsy depends on what is available and how urgent the result is. Tissue remains the reference when a recent block exists, while plasma testing is attractive when a new invasive procedure would delay care. Some laboratories report plasma results first and use tissue to confirm uncertain findings. This flexibility is one reason a panel-based approach fits modern thoracic oncology workflows, where speed and breadth both matter for treatment selection.

FAQ

Q: Does this test require a fresh surgical biopsy? A: NGS can be performed on formalin-fixed paraffin-embedded tissue, so an existing diagnostic block is often sufficient provided it contains adequate tumor content.

Q: How does a 20-gene panel differ from a single-gene test? A: A single-gene test looks for one known alteration, whereas a panel screens many drivers simultaneously, which is far more efficient when tissue is scarce.

Q: Can the assay be run on blood instead of tissue? A: Many NGS workflows support plasma cell-free DNA, often called a liquid biopsy, which is useful when tissue is unavailable or when monitoring emerging resistance is the goal.